82TiP A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies

A.G. Gianoukakis; S.M. Arnold; S.A. Kahn; M. Taylor; E. Garralda; M.G. Krebs; H-T. Arkenau; L. Clark; G. Fisher; V. Subbiah

doi:10.1016/S1556-0864(23)00336-2

82TiP A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies

A.G. Gianoukakis, S.M. Arnold, S.A. Kahn, M. Taylor, E. Garralda, M.G. Krebs, H-T. Arkenau, L. Clark, G. Fisher, V. Subbiah

Research output: Contribution to conference › Abstract › peer-review

Original language	English
Pages	S87-S88
DOIs	https://doi.org/10.1016/S1556-0864(23)00336-2
Publication status	Published - 1 Apr 2023
Event	European Lung Cancer Congress 2023 - Copenhagen, Denmark Duration: 29 Mar 2023 → 1 Apr 2023

Conference

Conference	European Lung Cancer Congress 2023
Abbreviated title	ELCC 2023
Country/Territory	Denmark
City	Copenhagen
Period	29/03/23 → 1/04/23

Access to Document

10.1016/S1556-0864(23)00336-2

Cite this

Gianoukakis, A. G., Arnold, S. M., Kahn, S. A., Taylor, M., Garralda, E., Krebs, M. G., Arkenau, H.-T., Clark, L., Fisher, G., & Subbiah, V. (2023). 82TiP A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies. S87-S88. Abstract from European Lung Cancer Congress 2023, Copenhagen, Denmark. https://doi.org/10.1016/S1556-0864(23)00336-2

@conference{dbfe13c590644c4aa18563472f773c39,

title = "82TiP A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies",

author = "A.G. Gianoukakis and S.M. Arnold and S.A. Kahn and M. Taylor and E. Garralda and M.G. Krebs and H-T. Arkenau and L. Clark and G. Fisher and V. Subbiah",

year = "2023",

month = apr,

day = "1",

doi = "10.1016/S1556-0864(23)00336-2",

language = "English",

pages = "S87--S88",

note = "European Lung Cancer Congress 2023, ELCC 2023 ; Conference date: 29-03-2023 Through 01-04-2023",

}

Gianoukakis, AG, Arnold, SM, Kahn, SA, Taylor, M, Garralda, E, Krebs, MG, Arkenau, H-T, Clark, L, Fisher, G & Subbiah, V 2023, '82TiP A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies', European Lung Cancer Congress 2023, Copenhagen, Denmark, 29/03/23 - 1/04/23 pp. S87-S88. https://doi.org/10.1016/S1556-0864(23)00336-2

82TiP A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies. / Gianoukakis, A.G.; Arnold, S.M.; Kahn, S.A. et al.
2023. S87-S88 Abstract from European Lung Cancer Congress 2023, Copenhagen, Denmark.

Research output: Contribution to conference › Abstract › peer-review

TY - CONF

T1 - 82TiP A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies

AU - Gianoukakis, A.G.

AU - Arnold, S.M.

AU - Kahn, S.A.

AU - Taylor, M.

AU - Garralda, E.

AU - Krebs, M.G.

AU - Arkenau, H-T.

AU - Clark, L.

AU - Fisher, G.

AU - Subbiah, V.

PY - 2023/4/1

Y1 - 2023/4/1

U2 - 10.1016/S1556-0864(23)00336-2

DO - 10.1016/S1556-0864(23)00336-2

M3 - Abstract

SP - S87-S88

T2 - European Lung Cancer Congress 2023

Y2 - 29 March 2023 through 1 April 2023

ER -

Gianoukakis AG, Arnold SM, Kahn SA, Taylor M, Garralda E, Krebs MG et al.. 82TiP A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies. 2023. Abstract from European Lung Cancer Congress 2023, Copenhagen, Denmark. doi: 10.1016/S1556-0864(23)00336-2